2020
DOI: 10.1182/blood-2020-136044
|View full text |Cite
|
Sign up to set email alerts
|

Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

Abstract: Introduction : Glofitamab (RG6026) is a novel T-cell-engaging, bispecific, full-length antibody with a 2:1 molecular configuration that facilitates bivalent binding to CD20 on B-cells, and monovalent binding to CD3 on T-cells. Preclinically, glofitamab had superior potency compared with other tested bispecifics with 1:1 formats (Bacac, et al. Clin Cancer Res 2018). NP30179 (NCT03075696) is an ongoing multicenter, Phase I/Ib, dose-escalation and dose-expansion trial evaluating the safety, tolerability, pharmaco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
36
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 45 publications
(36 citation statements)
references
References 0 publications
0
36
0
Order By: Relevance
“…The safety profile of glofitamab was manageable, mostly ≤ grade 2 CRS. The step‐up dosing of glofitamab can be used as a CRS mitigation strategy in addition to obinituzumab pre‐treatment, allowing administration of a high target dose (30 mg) 80 …”
Section: Relapsed Refractory Diseasementioning
confidence: 99%
“…The safety profile of glofitamab was manageable, mostly ≤ grade 2 CRS. The step‐up dosing of glofitamab can be used as a CRS mitigation strategy in addition to obinituzumab pre‐treatment, allowing administration of a high target dose (30 mg) 80 …”
Section: Relapsed Refractory Diseasementioning
confidence: 99%
“…Glofitamab was then administered IV in a weekly step-up dosing regimen with a schedule of either 2.5/10/16 mg or 2.5/10/30 mg. Glofitamab was given every three weeks for up to 12 cycles. Interim data for NP30179 presented the results of 38 patients with R/R NHL who received glofitamab step-up dosing with Gpt [ 14 ]. There were 17 patients (45%) who received 2.5/10/16 mg and 21 patients (55%) who received 2.5/10/30 mg.…”
Section: Clinical Efficacymentioning
confidence: 99%
“…Patients received obinutuzumab pre-therapy to effectively mitigate high-grade CRS. Of the 8 efficacy-evaluable FL patients the ORR was 100%, with 75% achieving a CR [ 30 ]. The toxicity profile was manageable.…”
Section: T-cell Engaging Bispecific Antibodiesmentioning
confidence: 99%